loading page

Real-Life Use of First-Generation EGFR-TKI with Chemotherapy in EGFR-sensitive Mutations in Non-Small-Cell Lung Cancer: A Single-Center Analysis and Meta-Analysis
  • +7
  • Jiachun Sun,
  • Jingya Li,
  • Xinyang Li,
  • Junshuai Rui,
  • Dejiu Kong,
  • Haolin Shi,
  • Zihan Yang,
  • Zhiyi Jiang,
  • Guoqiang Miao,
  • She-Gan Gao
Jiachun Sun
Henan University of Science and Technology Affiliated First Hospital

Corresponding Author:[email protected]

Author Profile
Jingya Li
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Xinyang Li
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Junshuai Rui
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Dejiu Kong
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Haolin Shi
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Zihan Yang
Henan University of Science and Technology School of Medicine
Author Profile
Zhiyi Jiang
Henan University of Science and Technology Affiliated First Hospital
Author Profile
Guoqiang Miao
Henan University of Science and Technology Affiliated First Hospital
Author Profile
She-Gan Gao
Henan University of Science and Technology Affiliated First Hospital
Author Profile

Abstract

Background: Recently,epidermal growth factor receptor (EGFR) -targeting drugs have benefited thousands of patients with EGFR mutation-positive (EGFR MUT+) non-small-cell lung cancer (NSCLC). Nevertheless, nearly all patients with NSCLC who were sensitive to first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), finally developed resistance. Therefore, numerous clinicians have focused on improving the clinical effect of first-generation EGFR-TKIs (1st-gen EGFR-TKIs). Methods: To analyze the therapeutic outcomes of individuals with progressive NSCLC, a retroactive assessment was performed on 86 patients who were medicated with only icotinib or combined with pemetrexed and platinum-based chemotherapy at The First Affiliated Hospital of Henan University of Science and Technology (HAUST). Results: Eighty-six patients with NSCLC-bearing EGFR-sensitive mutations were retroactively analyzed. The results showed statistical significance in PFS (P = 0.049) and disease control rate DCR (P = 0.031) between icotinib + chemotherapy and icotinib alone, especially in the brain metastases (P = 0.021) and L-858R mutation subgroups (P = 0.05). According to the findings of the multivariate analysis, treatment (P = 0.033) and EGFR mutation status (P = 0.019) were significant predictive variables. The OS comparison between icotinib + chemotherapy and icotinib alone were not significantly different. The study included a total of 1242 patients, of which 648 obtained combined treatment and 594 obtained first-generation EGFR-TKI monotherapy. Analyzing the relevant data from multiple studies, the results showed significant improvements in ORR (RR: 0.63, 95% CI: 0.49–0.82, P = 0.0006), PFS (RR: 0.61, 95% CI: 0.47–0.79, P = 0.0002), and OS (RR: 0.67, 95% CI: 0.51–0.88, P = 0.004) for those on combination therapy. However, there was also an increase in treatment-emergent AEs among these patients. Conclusion: In summary, administering first-generation EGFR-TKI concurrently with chemotherapy provides an edge in the therapeutic management of locally or severely advanced NSCLC that is EGFR-positive. Therefore, EGFR mutation-positive NSCLC (EGFR MUT+ NSCLC) patients in this condition may find it advantageous to consider using 1st-gen EGFR-TKIs in conjunction with chemotherapy (1st-gen EGFR-TKIs + Chemo).
18 Sep 2023Submitted to Cancer Reports
22 Sep 2023Submission Checks Completed
22 Sep 2023Assigned to Editor
22 Sep 2023Review(s) Completed, Editorial Evaluation Pending
05 Oct 2023Reviewer(s) Assigned